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Abstract
Purpose: The expression of the major histocompatibility complex class I (MHC-I) in the brain has received
considerable interest not only because of its fundamental role in the immune system, but also for its non-immune
functions in the context of activity-dependent brain development and plasticity.
Methods: In the present study we evaluated the expression and cellular pattern of MHC-I in focal glioneuronal
lesions associated with intractable epilepsy. MHC-I expression was studied in epilepsy surgery cases with focal
cortical dysplasia (FCD I, n = 6; FCD IIa, n = 6 and FCD IIb, n = 15), tuberous sclerosis complex (TSC, cortical tubers;
n = 6) or ganglioglioma (GG; n = 15) using immunocytochemistry. Evaluation of T lymphocytes with granzyme-B+
granules and albumin immunoreactivity was also performed.
Results: All lesions were characterized by MHC-I expression in blood vessels. Expression in both endothelial and
microglial cells as well as in neurons (dysmorphic/dysplastic neurons) was observed in FCD II, TSC and GG cases.
We observed perivascular and parenchymal T lymphocytes (CD8+, T-cytotoxic) with granzyme-B+ granules in FCD
IIb and TSC specimens. Albumin extravasation, with uptake in astrocytes, was observed in FCD IIb and GG cases.
Conclusions: Our findings indicate a prominent upregulation of MHC-I as part of the immune response occurring
in epileptogenic glioneuronal lesions. In particular, the induction of MHC-I in neuronal cells appears to be a feature
of type II FCD, TSC and GG and may represent an important accompanying event of the immune response,
associated with blood–brain barrier dysfunction, in these developmental lesions.
Keywords: Focal cortical dysplasia, Ganglioglioma, Cortical tubers, Neurons, Microglia, Major histocompatibility
complex (MHC) class I
Introduction
Recent clinical and neuropathological evidence supports
the critical role of a sustained inflammatory reaction in
glioneuronal lesions with activation of both the innate
and the adaptive immune response and involvement of
different inflammatory pathways (for reviews see [1-4]).
Interestingly, proinflammatory molecules have been
shown to alter neuronal excitability and, in experimental
models, to decrease the seizure threshold, contributing
to neuronal cell death [2-4].
According to the current histopathological classifica-
tion system [5], focal cortical dysplasia (FCD) has been
classified into type I, characterized by cortical dyslami-
nation (with three FCD subtypes according to the pat-
tern of dyslamination), and type II, characterized by
additional cytological abnormalities (FCD IIa with dys-
morphic neurons and FCD IIb with dysmorphic neurons
and balloon cells).
In a recent study [6], we confirmed the occurrence of
complex inflammatory changes (involving both glial and
neuronal cells) in FCD specimens and demonstrated that
the severity of these changes is greater in FCD IIb than
in specimens from patients with FCD I. The activation
of components of the adaptive immunity, with the pres-
ence of T lymphocytes (CD8+, T-cytotoxic/suppressor
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immunophenotype), has also been mainly observed in
FCD IIb specimens [6].
Whether these inflammatory changes represent a fea-
ture common to different developmental glioneuronal
lesions and whether induction of major histocompatibil-
ity complex (MHC) class I molecules may be involved
still needs to be clarified.
MHC-I molecules play a fundamental role in the
immune system, in particular in the context of the adap-
tive immune response, but have also been shown to have
non-immune functions, being involved in the regulation
of activity-dependent brain development and plasticity
(for a review see [7]). Interestingly, glial and neuronal
MHC-I upregulation has been observed in brain
specimens from patients with Rasmussen’s encephalitis
(a severe inflammatory epileptic encephalopathy of
childhood) and intractable epilepsy and it has been sug-
gested that it plays a critical role in antigen-specific cyto-
toxicity [8,9].
The aim of the present study was to determine
whether MHC-I is induced in focal glioneuronal lesions
associated with intractable epilepsy. We evaluated the
cellular distribution of MHC-I within a large spectrum
of glioneuronal lesions, including focal cortical dysplasia
type I, type IIa and type IIb, cortical tubers from patients
with tuberous sclerosis complex (TSC) and ganglioglio-
mas (GGs). Additionally, the presence of T lymphocytes
with granzyme-B+ granules and albumin immunoreactiv-




We examined a total of 48 surgical specimens: 6 FCD I
(3, Ia; 3, Ib), 6 FCD IIa, 15 FCD IIb, 6 cortical tubers
from patients with TSC and 15 GG. The cases included
in this study were obtained from the departments of
neuropathology of the Academic Medical Center (Uni-
versity of Amsterdam, UvA) in Amsterdam and the Uni-
versity Medical Center in Utrecht (UMCU), the
Netherlands. The clinical characteristics derived from
the patients’ medical records are summarized in Table 1.
Patients underwent therapeutic surgical resection for re-
fractory epilepsy and had, predominantly, medically in-
tractable complex partial seizures. The postoperative
seizure outcome was classified according to Engel [10].
All the patients included in our series did not have any
apparent seizure activity in the 24 h before surgery.
Patients who underwent implantation of strip and/or
grid electrodes for chronic subdural invasive monitoring
before resection were excluded from this study.
To grade the degree of FCD, we followed the inter-
national consensus classification recently proposed [5].
All patients with cortical tubers fulfilled the diagnostic
criteria for TSC [11]. For GG, we used the revised WHO
classification of tumors of the central nervous system
[12]. In five patients (one FCD, one TSC and three GG)
a significant amount of perilesional tissue (normal-
appearing cortex/white matter adjacent to the lesion)
was resected as well. Brain tissue from patients with viral
encephalitis (rabies encephalitis [13]; herpes simplex en-
cephalitis (female, age at autopsy: 69 years) and Rasmus-
sen’s encephalitis (n = 6; 4 females and 2 males; mean
age at surgery: 20.6 years, range: 16 to 26) were also
examined as positive controls. In addition, normal-
appearing control cortex/white matter was obtained at
autopsy from six young adult control patients (Table 1),
without a history of seizures or other neurological dis-
eases. All autopsies were performed within 12 h after
death. Informed consent was obtained for the use of
brain tissue. Tissue was obtained and used in a manner
compliant with the Declaration of Helsinki.
Table 1 Summary of clinical findings for epilepsy patients and controls




Mean age at surgery
(years/range)
Localization Mean duration of
epilepsy (years/range)
FCD I 6 3/3 27.8 (19 to 39) 4 Temporal 7.7 (6 to 13)
2 Frontal
FCD IIa 6 3/3 24.3 (11 to 24) 3 Frontal 6.1 (2 to 11)
3 Temporal
FCD IIb 15 7/8 23.2 (17 to 41) 8 Temporal 7.8 (3 to 15)
7 Frontal
Cortical tubers (TSC) 6 3/3 17.8 (5 to 35) 3 Frontal 13.5 (2.8 to 34)
3 Temporal
2 Parietal
GG 15 8/7 29.2 (15 to 46) Temporal 7.8 (3 to 15)
Controls (no epilepsy) 6 3/3 30.1 (20 to 41) Temporal -
FCD, focal cortical dysplasia; TSC, tuberous sclerosis complex; GG, ganglioglioma.
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Tissue preparation
Formalin-fixed, paraffin-embedded tissue samples (one
representative paraffin block per case containing the
complete lesion or the largest part of the lesion resected
at surgery) were sectioned at 6 μm and mounted on pre-
coated glass slides (Star Frost, Waldemar Knittel GmbH,
Braunschweig, Germany). Sections of all specimens were
processed for hematoxylin eosin, luxol fast blue and
Nissl stains as well as for immunocytochemical stainings
for a number of neuronal and glial markers, which are
described below.
Immunocytochemistry
The primary antibodies used in the study are summarized
in Table 2. Single-label immunocytochemistry was devel-
oped using the Powervision kit (Immunologic, Duiven, the
Netherlands). 3,3-diaminobenzidine (Sigma, St Louis, USA)
was used as the chromogen. Sections were counterstained
with hematoxylin.
For double-labeling of MHC-I with GFAP, MAP-2 or
pS6 (as well as of albumin with CD31 or GFAP and GrB
with GFAP) sections were, after incubation with the pri-
mary antibodies overnight at 4°C, incubated for 2 h at
room temperature with Alexa FluorW 568-conjugated
anti-rabbit and Alexa FluorW 488 anti-mouse immuno-
globulin G (IgG) or anti-goat IgG (Molecular Probes,
The Netherlands; 1:100). Sections were then analyzed
using a laser scanning confocal microscope (Leica TCS
Sp2, Wetzlar, Germany).
For double-labeling of MHC-I with NeuN, sections
were incubated with the first primary antibody. Anti-
MHC-I was visualized with a polymer-alkaline phosp-
hatase (AP)-labeled anti-rabbit antibody (BrightVision
#DPVM55AP, Immunologic, Duiven, The Netherlands)
and Vector Red (AP substrate kit III, #SK-5100, Vector
labs, Burlingame, CA, USA) as the chromogen. To re-
move the first primary antibody (MHC-I), the sections
were incubated at 121°C in a citrate buffer (0.01 M,
pH 6.0) for 10 min. Sections were then incubated
for 1 h at room temperature with the second pri-
mary antibody (NeuN). The second primary anti-
bodies were visualized with poly-AP anti-rabbit
antibody (BrightVision #DPVM55AP, Immunologic,
Duiven, The Netherlands) and Vector Blue (AP sub-
strate kit III, #SK-5300, Vector labs, Burlingame, CA,
USA) as the chromogen.
Evaluation of immunostaining
All labeled tissue sections were evaluated by two inde-
pendent observers blind to clinical data, for the presence
or absence of various histopathological parameters and
specific immunoreactivity for the different markers. Two
representative sections per case were stained and
assessed for the MHC-I and albumin. The intensity of
the staining was evaluated as previously described [6,14],
using a semi-quantitative scale ranging from 0 to 3 (0:
negative; 1: weak; 2: moderate; 3: strong immunoreac-
tivity). All areas of the specimen were examined and the
score represents the predominant cell staining intensity
found in each case. The approximate proportion of cells
(microglia, neurons and endothelial cells/blood vessels)
showing MHC-I immunoreactivity (1: single to 10%; 2:
11% to 50%; 3: >50%) was also scored to give informa-
tion about the relative number (‘frequency’ score) of
positive cells within the specimens with a malformation
of cortical development. In the case of a disagreement,
independent reevaluation was performed by both obser-
vers to define the final score. As proposed before
[6,15], the product of these two values (intensity and
frequency scores) was taken to give the overall score
Table 2 Immunocytochemistry: primary antibodies
Antigen Primary antibody Source Dilution
Glial fibrillary acidic protein (GFAP) Polyclonal rabbit DAKO, Glostrup, Denmark 1:4,000
Neuronal nuclear protein (NeuN) Mouse clone MAB377 Chemicon, Temecula, CA, USA 1:2,000
HLA-DP, DQ, DR (MHC-II) Mouse clone CR3/43 DAKO, Glostrup, Denmark 1:1000
HLA-A, B, C (MHC-I) Mouse clone HC-10 Gift from Prof. J. Neefjes, NKI, the Netherlands 1:200
Vimentin Mouse clone V9 DAKO, Glostrup, Denmark 1:400
Neurofilament (NF) Mouse clone SMI311 Sternberger Monoclonals, Lutherville, MD, USA 1:1,000
Microtubule associated protein (MAP2) Mouse clone HM2 Sigma,St. Louis, IL, USA 1:100
Microtubule associated protein (MAP2) Polyclonal rabbit Millipore, Billerica, MA, USA 1:500
Phospho-S6 ribosomal protein (pS6) Polyclonal rabbit (Ser235/236; pS6) Cell Signaling Technology, Beverly, MA, USA; 1:50
CD68 Mouse clone PG-M1 DAKO, Glostrup, Denmark 1:200
CD31 Mouse clone JC70A DAKO, Glostrup, Denmark 1:10
Albumin Rabbit polyclonal DAKO, Glostrup, Denmark 1:20,000
Granzyme B (GrB) Mouse clone GrB-7 Monosan, Uden, The Netherlands 1:100
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(immunoreactivity total score), which is shown in
Figure 1 (MHC-I) and Figure 2 (albumin). Neuronal
cell bodies were differentiated from glia and glia-neuronal
balloon cells or giant cells based on morphology.
To analyze the percentage of double-labeled cells
positive for MHC-I and NeuN, digital images of eight
representative fields per section (magnification 20 times)
were collected (Leica DM5000B). Images were analyzed
with a Nuance VIS-FL Multi-spectral Imaging System
(Cambridge Research Instrumentation; Woburn, MA) as
previously described [16,17]. The total number of cells
stained with MHC-I or NeuN, as well as the number of
cells double labeled with both were counted visually and
percentages were calculated (expressed as mean ± SEM)
of cells co-expressing NeuN and MHC-I.
Quantitative analysis was performed for GrB and the
numbers of positive cells were quantified as previously
described [15,18]. Quantitative analysis of the staining
intensity in endothelial cells was also performed. The
relative optical density ratio (ODR) of endothelial cells
immunolabeled with MHC-I was calculated as previ-
ously described [19]. The degree of MHC-I expression
in microvessels was evaluated by counting the numbers
of vessels expressing the protein in two non-overlapping
microscopic fields (field size 1 mm2) of control and FCD
IIb specimens (n = 6 in each group). Results were
expressed as a normalized mean ± SEM of MHC-I posi-
tive vessels per microscopic field, taking into account
the total number of microvessels in control and FCD
specimens, assessed by counting the number of CD31-
positive vessels in adjacent serial sections, as previously
described [20].
Statistical analysis
Statistical analyses were performed with SPSS for
Windows (SPSS 11.5, SPSS Inc., Chicago, IL, USA). The
Figure 1 Evaluation of MHC-I expression in control and FCD I, FCD IIa, FCD IIb, TSC and GG. (A) and (B): MHC-I immunoreactivity scores
(total score; see material and methods for details) in microglial cells and neurons. (C): Graph showing percentages of neuronal cells
immunoreactive for NeuN and co-expressing MHC-I. Data are expressed as mean ± standard error of mean (SEM). P < 0.05 compared to FCD I
and controls. FCD, focal cortical dysplasia; TSC, tuberous sclerosis complex; GG, ganglioglioma; MHC-I, major histocompatibility complex class I;
ND, not determined; nd, not detectable.
Figure 2 Evaluation of GrB positive cells and albumin immunoreactivity (IR) in astrocytes. (A): Graph showing GrB cell counting in control
cortex, FCD I, FCD IIa, FCD IIb and GG. * P < 0.05, compared to GG, FCD I, FCD IIa and controls. (B): Albumin immunoreactivity scores (total score;
see material and methods for details) in astrocytes.
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two-tailed Student’s t-test was used to assess differences
between groups. To assess differences between more
than two groups a non-parametric Kruskal–Wallis test
followed by a Mann–Whitney U test were used. Correl-
ation between immunostaining (number of positive cells)
and different clinical variables (duration of epilepsy, seiz-
ure frequency, age at surgery, age at seizure onset and
epilepsy outcome) were assessed using the Spearman’s
rank correlation test. A value of P < 0.05 was defined as
being statistically significant.
Results
Case material and histological features
The clinical features of the cases included in this study
are summarized in Table 1. All patients had a history of
chronic pharmaco-resistant epilepsy. Age at surgery,
seizure duration and seizure frequency were not statisti-
cally different between patients with FCD I, FCD II and
GG in this cohort. Postoperatively, 67% of patients in
this cohort were completely seizure free. In this study,
we excluded patients with a mild degree of cortical dys-
plasia (mild malformation of cortical development). The
FCD cases included displayed the histopathological fea-
tures of FCD Ib or FCD IIa and IIb, according to the
international consensus classification [5].
The histopathological features of the cortical tuber
samples included cortical dyslamination, giant cells, dys-
plastic neurons and astrogliosis [21,22]. TSC1 mutations
were detected in one patient and TSC2 mutations in five
patients. In agreement with previous studies [6,23-25],
the expression of pS6 (indicating the activation of the
mTOR signal transduction pathway) was observed
within all tubers, and FCD II and GG samples in our co-
hort. All of the 15 FCD IIb samples had a neuronal la-
beling index (frequency score) greater than 50%. Of the
6 FCD IIa samples with pS6-positive neuronal cells, 3
(50%) had a labeling index between 1% and 10%, and
the other 3 (50%) had a labeling index between 11%
and 50%. In contrast, pS6 protein expression was not
detected in FCD I cases, as in the normal control speci-
mens. The number of HLA-DR (MHC-II) immunoreac-
tive cells was not significantly different between FCD IIa
and IIb in our cohort, but was higher compared to FCD
I, as previously reported [6].
MHC-I expression in FCD I and II
In the cortical autopsy of the human control, as well as
in the normal-appearing cortex adjacent to the lesions
(not shown), MHC-I was confined to blood vessels, and
was not detected either in neurons or in glial cells in
both cortex and white matter throughout all cortical
layers (Figure 3A,B).
In agreement with previous observations, in both viral
[13] and Rasmussen’s encephalitis [8,9] immunoreactivity
for MHC-I was also detected in lymphocytes, microglial
cells, astrocytes and neurons (not shown).
In FCD I, MHC-I displayed an immunoreactivity pat-
tern as in the controls, with expression in blood vessels,
but no detectable immunoreactivity in glial or neuronal
cells (Figure 3C and Figure 1A,B); in one case weak
immunoreactivity was detected in a few microglial cells
(Figure 1A).
In FCD IIa and IIb, consistent MHC-I expression was
also observed in neurons and glial cells with the morph-
ology of microglial cells (Figure 3D,E,F,G and Figure 1A,
B). Double labeling confirmed MHC-I expression in cells
of the microglial/macrophage lineage (HLA-DR positive
cells; Figure 3 and inserts in 3E and 3G), in neurons
(MAP-2 and NeuN positive cells; not shown), but not in
astrocytes (Figure 3; insert (b) in 3E). The mean number
of MHC-I positive neurons was found to be significantly
higher in FCD IIb than in FCD IIa, whereas no signifi-
cant differences were detected compared to TSC and
GG specimens (Figure 1C). We did not detect MHC-I
expression in balloon cells (Figure 3E,G). MHC-I immu-
noreactivity in microvessel endothelium was not signifi-
cantly different compared to the control cortex (autopsy;
Table 3, and/or the perilesional cortex, not shown). No
significant correlation was found between the increased
MHC-I staining in neurons in FCD II and the different
clinical variables. However, a positive correlation was
detected between the MHC-I staining in microglia and
the duration of epilepsy (Spearman’s rank correlation co-
efficient for FCD II, r = 0.865 with P < 0.05).
MHC-I expression in cortical tubers (TSC)
The expression pattern of MHC-I in cortical tubers of
TSC patients resembled that observed in FCD II, with
MHC-I positive blood vessels, neurons and microglial
cells, but not astrocytes (Figure 3H,I and Figure 1A,B).
The mean number of MHC-I positive neurons was
found to be significantly higher in TSC than in FCD IIa,
whereas no significant differences were detected com-
pared to FCD IIb and GG specimens (Figure 1C). A
large majority of giant cells were negative for MHC-I,
only occasionally (in two cases) was MHC-I expression
detected in sporadic giant cells within the white
matter (Figure 3I). No significant correlation was found
between the increased MHC-I staining in neurons
in TSC and the different clinical variables. However, a
positive correlation was detected between the MHC-I
staining in microglia in TSC and the duration of epilepsy
(Spearman’s rank correlation coefficient for TSC,
r = 0.835 with P < 0.05).
MHC-I expression in GG
In GG specimens, MHC-I immunoreactivity was detec-
ted in blood vessels, neurons and microglial cells, but
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Figure 3 Distribution of MHC-I immunoreactivity (IR) in FCD, TSC and GG. (A)-(B) Control cortex (A) and white matter (wm; B): MHC-I IR in
blood vessels (arrows). (C) FCD I: MHC-I IR in blood vessels (arrows). (D) FCD IIa: MHC-I IR in blood vessels (arrows), dysmorphic neurons (DN;
asterisks) and microglial cells (arrowheads). Insert in (D) shows a neuron (asterisk) positive for MHC-I and both MHC-I and MHC-II IR in blood
vessels (arrows). (E)–(G) FCD IIb: strong MHC-I IR in cortex, (E) and (F) and wm, (G) with expression in DN (arrowheads in (E) and asterisk in (F)).
MHC-I IR was also detected in blood vessels (arrows in (E)) and in microglial cells (insert (a) in (E), arrowheads in (F) and (G)). The balloon cells are
negative (asterisks in (G)). Insert (b) in (E): absence of co-localization of MHC-I with GFAP in astrocytes. Insert (c) in (E) and the insert in (G):
co-localization of MHC-I with MHC-II in microglial cells (the arrow in (c) indicates a microglial cell). (H), (I) TSC: strong MHC-I IR in both cortex
(H) and wm (I) with expression in DN (arrowheads in (H)), blood vessels (arrows in (H) and (I)) and microglia (arrowhead in (I)). Giant cells
are negative (asterisks). MHC-I IR is occasionally detected in giant cells (insert in (I)). Insert (a) in (H): co-localization with NeuN. Insert (b) in
(H): co-localization with pS6. Insert (c) in (H): co-localization with MAP-2. (J) GG: MHC-I IR in dysplastic neurons (arrowheads; high magnification in
insert (a)) and blood vessels (arrow). Insert (b) in (J): co-localization with NeuN. Insert (c) in (J): co-localization with MHC-II in microglial cells. Insert
(d) in (J): absence of co-localization with GFAP. Scale bars: (A)–(C) and (E): 150 μm; (D), (G)–(I): 40 μm; (F): 25 μm; (J): 80 μm.
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not in tumor astrocytes (Figure 3J and Figure 1A,B). The
mean number of MHC-I positive neurons was found to
be significantly higher in GG than in FCD IIa, whereas
no significant differences were detected compared to FCD
IIb and TSC specimens (Figure 1C).
No significant correlation was found between the
increased MHC-I staining in neurons in GG and the
different clinical variables. However, a positive correl-
ation was detected between the MHC-I staining in
microglia and the duration of epilepsy (Spearman’s rank
correlation coefficient for GG, r = 0.847 with P < 0.05).
T lymphocytes with granzyme B+ granules
In agreement with previous observations [6,26,27],
inflammatory infiltrates in glioneuronal lesions, such as
FCD IIb, contain T lymphocytes (CD8+, T-cytotoxic
immunophenotype) (Figure 4A).
In FCD IIb and TSC, we detected CD8 positive cells
with granzyme-B+ granules. These cells were often peri-
vascularly located, but occasionally in the vicinity (or in
close opposition) to dysmorphic neurons and astrocytes
(Figure 4B,C,D,E and Figure 2A). Granzyme B immunor-
eactivity was not detected in FCD I or IIa, and only
occasionally (one case) in GG specimens (Figure 2A).
Albumin extravasation and immunoreactivity in
astrocytes
Alterations in blood–brain barrier permeability were
detected using albumin immunocytochemistry in FCD
IIb, TSC and GG specimens (Figure 4H,I,J,K,L and
Figure 2B). In FCD IIb and TSC specimens, albumin
immunoreactivity, with diffuse cytoplasmatic staining,
was detected in perilesional astrocytes and in perivascu-
larly located balloon/giant cells in FCD IIb and TSC
specimens (Figure 4H,I,J,K); double labeling confirmed
co-localization in GFAP positive cells (Figure 4J,K).
Strong albumin immunoreactivity was observed within
GG specimens in tumor astrocytes (Figure 4L and
Figure 2B).
Discussion
In the present study we provide evidence of neuronal
and microglial MHC-I expression in epileptogenic glio-
neuronal lesions. The neuronal expression of MHC-I
was, however, only detected in FCD II, but not in FCD I
specimens or in the perilesional region (despite the
absence of significant differences in seizure frequency
and duration). Interestingly, MHC-I expression in neu-
rons was significantly higher in FCD IIb compared to
FCD IIa and the large majority of balloon/giant cells did
not express detectable levels of MHC-I. These observa-
tions confirm the difference between FCD I and II [6],
suggest some differences between IIa and IIb and indi-
cate that induction of MHC-I is not simply an effect of
seizure activity.
Several studies demonstrate that expression of MHC-I
can be upregulated in glia and neurons in response to
different types of challenges, including injury, infections
(chronic and acute), central administration of endotoxins
and exposure to different cytokines ([28-33] reviewed in
[7]). Cytokines have been show to differentially regulate
MHC-I induction in neurons [31,34,35]. Previous studies
have demonstrated prominent expression of components
of the IL-1R/TLR signaling pathways in neuronal cells in
epileptogenic glioneuronal lesions [6,26,27,36]. Signaling
through these pathways leads to activation of the tran-
scription factor, nuclear factor-kappa B (NF-κB) [37].
Interestingly, it has been suggested that activation of
NF-κB plays a role in induction of MHC-I [38,39].
Thus, NF-κB-dependent mechanisms of regulation may
contribute to the more prominent MHC-I expression
detected in FCD II (associated with consistent activation
of IL-1R/TLR signaling pathways [6]) compared to
FCD I.
Endogenous peptides presented by MHC-I molecules
(called MHC-I peptides (MIPs) or the immunopepti-
dome) represent the key to self/non-self-discrimination
by cells of the immune system. In this respect, a recent
study confirmed previous observations indicating that
the immune system is tolerant to MIPs expressed at
physiological levels but may promote immune responses
towards self MIPs present in excessive amounts [40,41].
This may be important in the context, of the suggestion
that neuronal MHC-I expression mediates removal of
dysfunctional neurons [30]. The study by Caron et al.
also suggests that changes in mTOR signaling can affect
the expression of MHC-I and the repertoire of MIPs
presented by MHC-I [41]. These observations highlight
the complexity of MHC-I regulation and indicate the
need for further analysis of the effect of mTOR modula-
tion in lesions (such as FCD II, TSC and GG) in which
this pathway is involved. Interestingly, a recent study
suggests a novel viral etiology for FCD IIB [42], which
could explain the constitutive activation of mTOR, as
well as the induction of MHC-I, in this focal malforma-
tion of cortical development.
Interestingly, neuronal MHC-I expression has been
reported in Rasmussen’s encephalitis and it has been
Table 3 MHC-I immunoreactivity in microvessel
endotheliuma
Control (n = 6) FCD IIb (n = 6)
Intensity score 1.47 ± 0.06 1.52 ± 0.10
ODR 2.8 ± 0.3 3.1 ± 0.4
aScoring of the histological specimens was performed as described in the
Materials and methods section. Values represent the mean ± SEM of the
number of samples indicated in parentheses. ODR: relative optical density
ratio of CD31-immunolabeled endothelium.
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Figure 4 Granzyme B (GrB) and albumin immunoreactivity (IR). (A)–(E) Granzyme B (GrB) IR. (A) Perivascular CD8 positive cells (arrows) for
FCD IIb. (B) and (C) GrB positive cells (arrows) for FCD IIb around blood vessels and in the vicinity of dysmorphic neurons (asterisks). Insert in
(C) shows a GrB positive cell near an astrocyte (GFAP positive). (D) and (E) GrB positive cells in cortical tubers (arrows) for TSC, also the vicinity of
a dysmorphic neuron (asterisk in (D)). (F)–(L) Albumin IR. For FCD I (F) and FCD IIa (G) there is an absence of glial IR. Albumin IR was detected in
blood vessels (arrows). (H) and (I) FCD IIb: Albumin IR was detected in perivascular astrocytes (arrows). (J) and (K) TSC: Strong albumin IR was
detected within the tuber in the perivascular region with expression in giant cells (arrows). Insert (a) in (J) shows albumin in cells surrounding a
blood vessel (stained with CD31). Insert (b) in (J) and the insert in (K) show co-localization of albumin with GFAP within tubers. (L) For GG, there
is strong albumin IR within the tumor. The insert shows co-localization of albumin with GFAP in tumor astrocytes. Scale bars (A): 40 μm; (B): 25
μm; (C)–(E): 20 μm; (F)–(H), (J) and (K) (bar in (J)): 80 μm; (I), (L): 40 μm.
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suggested that it plays a critical role in antigen-specific
cytotoxicity [8]. MHC-I expression is necessary for
antigen-specific cytotoxicity mediated by CD8+ lympho-
cytes [43]. In this context, we also detected CD8+ T
lymphocytes with GrB in FCD IIB and TSC specimens
in the vicinity of neurons. The possible contribution of
a MHC-I restricted immune response to neuronal
injury, occurring in patients with developmental path-
ologies and intractable epilepsy [18,44], requires further
investigation.
MHC-I was also was found to be expressed in reactive
microglial cells. Upregulation in microglial cells has been
shown in both multiple sclerosis (MS) [45] and Rasmus-
sen’s encephalitis [8,9]. Interestingly, the microglial ex-
pression of MHC-I was significantly higher in FCD II
compared to FCD I, reflecting the more prominent acti-
vation of microglial cells observed in FCD II specimens
[6]. Moreover, MHC-I expression in microglia correlated
positively with the duration of epilepsy, suggesting that
the upregulation of MHC-I in these cells may also occur
later in epileptogenesis.
Astrocytes did not display MHC-I immunoreactivity.
Expression of MHC-I in astrocytes has also not been
observed in MS lesions [45]. Thus upregulation of
MHC-I in astrocytes appears to represent a specific fea-
ture of Rasmussen’s encephalitis and an MHC-I res-
tricted T-cell response has been suggested as critically
contributing to the occurrence of the astrocytic degener-
ation observed in this pathology [9].
MHC-I expression was not detected in balloon cells in
FCD IIb and in the large majority of giant cells in TSC.
Interestingly, expression of MHC-I has been detected in
the giant cells from different types of TSC-associated brain
lesions in fetal cases ranging from 23 to 34 gestational
weeks (GW) [46], indicating developmental changes in the
phenotype of giant cells. MHC-I expression in these cells
early in development may reflect their role as antigen-
presenting cells and may account for the dynamic changes
occurring early in development in TSC lesions.
We did not detect changes in the expression levels of
MHC-I in endothelial cells within the different lesions
examined. However, lesions (FCD IIB, TSC and GG)
with prominent inflammatory changes and MHC-I upre-
gulation in neurons and microglia displayed evidence of
alterations in blood–brain barrier permeability, with al-
bumin extravasation and uptake in astrocytes. These
observations confirm previous findings for TSC [26],
highlighting its similarity to FCD IIB and the differences
with FCD I.
Our findings distinguish type I from type II FCD and
indicate a prominent upregulation of MHC-I in neurons
and microglial cells as part of the immune response oc-
curring in epileptogenic glioneuronal lesions, such as
FCD II, TSC and GG.
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